Clinical trials: Metastases to Brain
Breast Neoplasms, Neoplasm Metastasis
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions…
- Trial name
- NCT01441596
- Testing
- Vinorelbine, Investigator's choice of treatment, afatinib
- Where
- 40 sites in United States, Canada and 6 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Breast Neoplasms, Brain Neoplasms
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth…
- Conditions
- Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- ELECTRA (NCT05386108)
- Testing
- Elacestrant, Abemaciclib
- Where
- 86 sites in United States, Belgium and 8 more
- Volunteers
- 73 people
- Sponsor
- Stemline Therapeutics, Inc.
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin…
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05241873
- Testing
- BLU-451, Carboplatin, Pemetrexed
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Blueprint Medicines Corporation
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Non-Small Cell Lung Cancer, Brain Metastases
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
The purpose of this study is to evaluate the efficacy of icotinib in combination with radiotherapy for NSCLC patients with brain metastases. The primary endpoint is PFS of intracranial lesions
- Trial name
- NCT03754530
- Testing
- Icotinib, WBRT or SRS
- Volunteers
- 162 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Breast Neoplasm, Brain Neoplasm
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.
- Conditions
- Breast Neoplasm, Brain Neoplasm, Second Neoplasm
- Trial name
- STOP (NCT00638963)
- Testing
- temozolomide
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastases of Central Nervous System, Melanoma
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)
The study implies a 2 step study design. Patients are enrolled into 3 separate groups for melanoma, breast, and non-small cell lung cancer. In the first step, 21 patients per disease group are enrolled.
- Conditions
- Metastases of Central Nervous System, Melanoma, Breast Neoplasm, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00831545
- Testing
- Temozolomide
- Volunteers
- 162 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases
SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.
- Trial name
- NCT00522951
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875), ProHance
- Where
- 20 sites in Japan
- Volunteers
- 165 people
- Sponsor
- Bayer
Metastatic Breast Cancer
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
- Trial name
- DB-07 (NCT04538742)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 72 sites in United States, Australia and 13 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Breast Cancer, Non-small Cell Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
- Trial name
- NCT02308020
- Testing
- Abemaciclib
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, HER2-positive Breast Cancer
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without…
- Trial name
- NCT05593094
- Testing
- ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer, HER2+ Breast Cancer
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
This study will assess the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previously failed trastuzumab.
- Trial name
- NCT01132664
- Testing
- BKM120, Trastuzumab, Capecitabine
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Secondary Stroke
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications.
- Trial name
- ROXI-DAISEN (NCT07876492)
- Testing
- Cenvacibart
- Volunteers
- 6,106 people
- Sponsor
- Regeneron Pharmaceuticals
Partial Onset Seizures, Epilepsy
A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older
The purpose of this study is to assess the safety of perampanel in the treatment of partial onset seizures in participants of age 12 years and older with epilepsy.
- Trial name
- NCT03836924
- Testing
- Perampanel
- Where
- 12 sites in India
- Volunteers
- 200 people
- Sponsor
- Eisai Pharmaceuticals India Pvt. Ltd
Brain Metastasis, Non-small Cell Lung Cancer
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
The study objective is to evaluate the safety and efficacy of patupilone with respect to early progression and response of patients with non-small cell lung cancer (NSCLC) metastatic to the brain, who have progressed after…
- Trial name
- NCT00219297
- Testing
- Patupilone
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures
Patients with medically refractory epilepsy will be treated by intracerebroventricular (ICV) delivery of valproate using an implantable drug pump system.
- Trial name
- NCT02899611
- Testing
- Valproate
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Cerebral Therapeutics LLC
Epilepsy
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy.
- Trial name
- NCT00698581
- Testing
- Brivaracetam
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 88 people
- Sponsor
- UCB Pharma
Malignant Melanoma
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases.
- Trial name
- NCT01253564
- Testing
- RO5185426
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
NSCLC Brain Metastasis
Tumor Treating Fields (TTF) in Combination with Stereotactic Radiosurgery(SRS) for Brain Metastases from Non-small Cell Lung Cancer.
This is a randomized, controlled, open-label, phase III trials. The main purpose of this study is to evaluate the effectiveness and safety of tumor treating felds (TTF) combined with stereotactic radiosurgery (SRS) in the…
- Trial name
- NCT06716775
- Testing
- Tumor treating felds (TTF), Best Standard of Care
- Volunteers
- 200 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd